Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

NCT03989635 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Asthma
Asthma, Bronchial
Bronchial Asthma
Eosinophilia
Physiological Effects of Drugs

Interventions

DRUG: QAW039

Sponsor

Novartis Pharmaceuticals